好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Assessing Conductivity in the Cortical-Spinal Pathway Using Motor Evoked Potentials in Multiple Sclerosis and Neuromyelitis Optica Patients
MS and Related Diseases
P05 - (-)
185
BACKGROUND: Multiple sclerosis (MS) could affect conduction speed by focal demyelination along the pathway and/or diffuse damage throughout the normal appearing white matter. Transcranial magnetic stimulation allows measurement of centrally evoked motor evoked potentials (MEPs), which provide sensitive, reproducible measures of central motor conduction time. Neuromyelitis optica (NMO) is associated with more severe focal damage, but perhaps, less diffuse brain dysfunction as compared to MS. Thus, MEPs may both provide quantitative measures of central motor conductivity, and also distinguish NMO from MS.
DESIGN/METHODS: Age and gender matched MS and NMO patients were recruited at a single center (UBC Hospital MS and NMO clinic). MEPs were assessed in a single session; MRIs were also completed and used to guide TMS application via a stereotaxic system. MEPs were analyzed for onset latency, maximal peak-to-peak amplitude, and the difference between latency and peripheral conduction time.
RESULTS: To date, data has been collected and analyzed from 4 NMO and 5 MS subjects. The NMO group exhibited longer average latency (26.2 SD 5.71 versus 22.8 SD 7.02 milliseconds) and reduced MEP amplitudes (270 SD 211 versus 457 SD 404 microvolts) compared to MS.
CONCLUSIONS: These preliminary data suggest that individuals with NMO demonstrate less cortical excitability (as measured by onset latency and MEP amplitudes) as compared to individuals with MS. Further, they indicate that TMS based measures may be sensitive to differences in neuroelectrophysiology between individuals with NMO and MS. Future work will consider the relationship between MEP response and MRI myelin water fraction to further support the use of MEPs as a reliable tool in the assessment of functional abnormalities in MS and NMO patients.
Authors/Disclosures
Praveena Manogaran (USZ, Clinic for Neurology)
PRESENTER 		No disclosure on file
Aksel Siva, MD (Istanbul University Cerrahpasa School of Medicine) Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ali Raif Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanovel Pharmaceuticals, Turkiye. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abdi Ibrahim Ilac - TR. Dr. Siva has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono . The institution of Dr. Siva has received research support from Turkish MS Society. The institution of Dr. Siva has received research support from The Scientific and Technological Research Council Of Turkey - Health Sciences Research Grants.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Shannon Kolind, PhD, MSc, BSc (University of British Columbia) Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Kolind has received research support from Sanofi Genzyme. The institution of Dr. Kolind has received research support from Roche. The institution of Dr. Kolind has received research support from Biogen.
No disclosure on file
No disclosure on file
David K. Li, MD (University of British Columbia) Dr. Li has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Academy of Health Care Learning. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Consortium of MS Centers.
Anthony Traboulsee, MD (University of British Columbia) Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Consortium of MS Centers. The institution of Dr. Traboulsee has received research support from MS Canada. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Workshop Chair with Consortium of MS Centers.